cyrilzakka/clinical-trials huggingface dataset:
Effects of Blood Flow Restriction Training in Rotator Cuff Related Shoulder Pain

Blood flow restriction training is widespread in sport performance areas, where it has proven to be beneficial in strength and hypertrophy development. However, there are only few studies related to its effects on subjects with pathology, and currently, there is no recent clinical trial evaluating its effects on patients with RCRSP. We are aiming to define the potential benefits, acute and short-term effects of adding blood flow restriction to a low-load exercise training for patients with RCRSP.


Eligibility Criteria:
Inclusion Criteria:

* Pain around the antero-lateral (deltoid area) region of the proximal shoulder during active movements in abduction and/or external rotation.
* 3/5 positive impingement tests: Neer, Hawkins-Kennedy, empty can, painful arc, and resisted external rotation or abduction.
* Pain at rest less than 3cm in a visual analogue scale (VAS).

Exclusion Criteria:

* Previous shoulder surgery.
* Being treated with physical therapy or pharmacogical therapy for shoulder pain.
* External rotation range of motion less than 45º or 50% compared to the contralateral side.
* Suspected shoulder instability (previous dislocation/subluxation, sulcus sign, anterior drawer test, anterior/posterior aprehension test, relocation test).
* Suspected cervical radiculopathy (distraction, spurling, ULNT1, squeeze test, ipsilateral rotation less than 60º)
* Presence of neck pain.
* Suspected rotator cuff tears (drop arm test, external rotation lag sign, diagnostic imaging).
* Contraindications to blood flow restriction therapy.
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure

Several large trials have shown that beta-blocker treatment reduces the risk of death and hospital admission in patients with symptomatic heart failure. Unfortunately, survey data suggests relatively poor utilisation of beta-blockers, despite ample evidence for good tolerability. Additionally there are several important unanswered questions, such as clinical efficacy for specific sub-populations (women, the elderly and patients with diabetes or other co-morbidities) and the effect of beta-blockers in combination with other medications. Previous meta-analyses, based on published tabular data, have been conducted although this approach has important biases and limitations.

We plan to perform a carefully conducted systematic review of individual patient data from the major randomised trials of beta-blockers in heart failure. The goals of this collaborative project are to clarify the overall efficacy of beta-blockers and identify sub-groups that show particular benefit, thereby increasing the use of beta-blockers, reducing adverse clinical outcomes and the high costs associated with this condition.


Eligibility Criteria:
Inclusion Criteria:

* Randomised control trials of beta-blocker versus control in patients with documented heart failure
* Unconfounded trials only (in which one treatment group differed from another only by the beta-blocker therapy of interest)
* Randomization process precluded prior knowledge of the next treatment (for example trials in which treatment allocation was alternate or based on odd or even dates would not be included)

Exclusion Criteria:

* Trial sample size of less than 300 patients
Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring

This study aimed to evaluate the efficacy of dermaroller and topical vitamin C- either separate or combined- in treatment of post acne scars.

prospective randomized clinical trial that was The study was a randomized controlled trial, conducted in Sohag Dermatology outpatient clinic between June 2016 and of February 2018. 30 patients with acne scars were included.

All patients were informed about the entire procedure, medication, possible side effects and outcomes. A written informed consent was signed from each participant.

Study population:

Each study group included 10 patients. Detailed history and full clinical examination was conducted for each patient. Patients had 6 visits at one month interval to receive treatment and evaluated one month after the end of treatment visits.

The first group:

Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.

The second group:

Received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vit.C serum plus once daily application in between sessions.

The third group:

received once daily topical vit.C serum capsule at night for six months. With monthly evaluation.

Assessment of patients during visits was as follow:

A) Clinical evaluation by B) Photographic documentation C) Patient satisfaction D) Safety assessment

Eligibility Criteria:
Inclusion Criteria:

* Facial acne scars

Exclusion Criteria:

* Active inflammatory acne.
* Active infection in the treatment area (e.g., herpes simplex and verrucae).
* Melanoma or lesions suspected of malignancy.
* Isotretinoin use in the past year.
* Dermatoses (e.g., eczema and psoriasis).
* Sunburn.
* Anticoagulant therapy.
* Systemic disease (diabetes, hypertension, collagen disease or bleeding tendency).
Urdu Translation and Cross Cultural Validation of PedsQL Inventory Infant Scale Parent Report 1 to 12 Months

The current study aimed to translate and validate Urdu version of that module from PedsQL, to measure the "quality of life" outcomes for Pakistan and Urdu speaking people.

Data will be collected by PedQL Infants Scale Parent report A mix method approach will be applied Forward translation Backward translation Review of forward and backward translation The process of translation will be followed the guidelines in the translation manual. Translators will translate the PedsQL Inventory Infants Scale Parent Report independently from each other in Urdu language following the proper forward and backward translation procedure.

Data Analysis Quality of life pediatric population will assess through Urdu translated version of PedsQL Inventory Infants Scale Parent report. Data will be analyzed through SPSS.

Eligibility Criteria:
Inclusion Criteria:

* Parents of both genders included
* Parents of infant age 1 to 12 months were included.

Exclusion Criteria:

* Parents suffering from psychological disorders
* Parents with severe behavior issue
* Parents who cannot understand Urdu
Prevalence of the Signs and Symptoms of TMD in Adolescents

the Prevalence of the Signs and Symptoms of Tempro-mandibular Joint Disorder in a sample of Egyptian adolescents

Our study is observational cross sectional study to evaluate the prevalence ofTempro-mandibular Joint Disorder( TMDs) in Egyptian adolescents based on Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD) .The following examinationwill be done for each patient and recorded in his/her chart:

Include maximal mandibular opening capacity, joint noises, deviation of mandible during opening and closing, tenderness of the TMJ and masticatory muscles, headache and pain in TMJ area.

All clinical examinations will be carried out by one investigator. Examination of TMJ disorders include the following aspects: I) Examination of TMJ sounds (clicking and crepitus) using a stethoscope over the TMJ area and by having the patient open and close the mouth.

II) Associated muscle disorders will be determined by:

1. palpation of TMJ area.
2. digital palpation and functional manipulation of the masticatory muscles according to Okeson.

Eligibility Criteria:
Inclusion Criteria:

* Adolescents(age range10-18 years old).
* A well-defined dentalCl I, Cl II/1, Cl II/2, and Cl III relationship (Angle Classification).
* Mixed and permanent dentition.
* Both sexes.
* Normal skeletal pattern

Exclusion Criteria:

* Adolescents with syndromes.
* Systemic diseases affecting bones.
* Adolescents with rheumatoid arthritis.
* Previous trauma in the face.
* Neurological disorders.
* Psychiatric disorders.
* Neoplasia.
* Adolescents who had received orthodontic treatment.
X-Chromosome Inactivation Status and Premature Ovarian Failure

Women who are affected with premature ovarian failure will exhibit skewed X-chromosome inactivation patterns compared to women with normal menstrual function (as defined by being pregnant), indicating a possible X-chromosome defect.

Premature ovarian failure (POF) affects approximately 1% of women. For most women a cause is not found, but structural abnormalities of the X-chromosome commonly lead to POF, suggesting genes on the X-chromosome are necessary for normal ovarian function. It is known that certain gene mutations on the X-chromosome can lead to changes in the normal random pattern of X-chromosome inactivation in females.

We propose to study X-inactivation patterns in a cohort of women with idiopathic POF, and compare their pattern to a mean age-matched cohort of women with normal menstrual function.

We hypothesize that some women with POF will show skewed X-inactivation, suggesting a mutation on the X-chromosome as the etiology of their POF.

Eligibility Criteria:
Inclusion Criteria:

* Women diagnosed with POF.
* A chromosomal analysis must have been performed to evaluate X-chromosomal abnormalities, and the results are known to be normal.

Exclusion Criteria:

* Patients who have a known etiology for their POF and/or an inability to obtain karyotype results for these patients or unknown X-chromosome abnormalities.
Development of an Early Warning Score for Detecting the Deterioration of a Patients' General Condition in an Acute Hospital

An acute deterioration of a patients' general condition is often preceded by changes in individual vital parameters. An early warning system (EWS) shall be developed with a reduced number of physiological and individual parameters, compared to conventional early warning systems; and an algorithm will be generated that is able to predict clinical deterioration. Its predictive power and accuracy shall be investigated. In a second exploratory phase, different model variants will be analyzed and the applicability of the model variants in the context of continuous EWS on wearables will be examined.

An acute deterioration of a patients' general condition is often preceded by changes in individual vital parameters and may lead to adverse events, such as admission to the intensive care unit, heart attack or death. Some of them are potentially avoidable if appropriate measures are taken in a timely manner. Therefore early warning systems (Early Warning Scores= EWS) have been developed from a set of several physiological measurements, signs and symptoms. Individual parameters are weighted to sum up a score.

Based on this score, the deterioration of a patients' general condition may be indicated and a predetermined reaction from the professional staff be triggered (so-called track-and-trigger system). It is important to determine all parameters since missing values influence the informative value of an EWS. This requires a higher effort by the staff and is one of the reasons why early warning systems are not yet used systematically in Switzerland.

A reduction in the number of parameters to be measured could lower the hurdle for the use of these tools and enable a broader applicability. Therefore an early warning system shall be developed with a reduced number of physiological and individual parameters, compared to conventional early warning systems; and an algorithm will be generated that is able to predict clinical deterioration. Its predictive power and accuracy shall be investigated, based on various clinical outcomes such as mortality, cardiac arrest, transfer to the intensive care unit or sepsis. Retrospective, encrypted patient data (from 2016 until 2022) will be used to develop a statistical prediction model. In a second exploratory phase, different model variants will be analyzed and the applicability of the model variants in the context of continuous EWS on wearables will be examined.

Eligibility Criteria:
Inclusion Criteria:

* Hospitalized patients of surgical and medical wards of University Hospital Basel
* Hospital stay longer than 24 hours
* Signed general consent

Exclusion Criteria:

* Patients admitted directly to the intensive care unit
* Rejection of general consent
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent prior to any study-related procedure not part of normal medical care;
* Male or female ≥ 18 years of age;
* If female of childbearing potential; willing to practice reliable birth control measures during study treatment and for at least 28 days after study completion, not lactating or pregnant, and has a documented negative pregnancy test result within 24 hours prior to study medication administration;
* End-stage renal disease on stable (for at least 2 weeks) hemodialysis regimen, three times weekly using high-flux membranes;
* Functioning hemodialysis access (for example, graft or fistula);
* Considered to be in appropriate health for study entry by the Investigator (for example, no acute, debilitating medical problems) and appropriate candidate for completing study treatment;
* If taking concomitant medications, subject must be on a relatively stable dose for at least two weeks prior to study drug administration.

Exclusion Criteria:

* Received an investigational drug (including experimental biologic agents) within 30 days of study drug administration;
* Has received any dose of daptomycin within 7 days prior to study drug administration;
* Known to be allergic or intolerant to daptomycin;
* Evidence of active ongoing infection;
* Known human immunodeficiency virus (HIV) infection with CD4 count ≤ 200 cells/mm3;
* Active illicit drug use or alcohol abuse;
* Myocardial infarction within last 6 months;
* Subject with a history of muscular disease (for example, polymyositis, muscular dystrophy);
* Subject with a history of neurological disease (for example, Guillain Barré, multiple sclerosis), except stroke \> 6 months prior to study entry;
* Intramuscular injection within 7 days of study drug administration;
* Body mass index (BMI) ≤ 18.5 or ≥ 40 kg/m2 (BMI = weight \[kg\]/height \[m2\]);
* WBC ≥ 12, 000 cells/mm3 or ≤ 2500 cells/ mm3;
* Neutropenic subject with absolute neutrophil count ≤ 500 cells/mm3;
* Baseline CPK values ≥ 3X ULN (upper limit of normal);
* Alanine aminotransferase (ALT) \> 5XULN;
* Aspartate aminotransferase (AST) \> 5XULN;
* Hemoglobin ≤ 9 gm/dL;
* Is considered unlikely to comply with study procedures or to return for scheduled post-treatment evaluations;
* History of rhabdomyolysis.
Greek Registry - Familial Hypercholesterolaemia

Familial hypercholesterolemia (FH) \[heterozygous (heFH) or homozygous FH (hoFH)\] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.

In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world \<5% of individuals with FH are identified .

Until lately the prevalence of heFH was traditionally considered to be \~ 1:500 individuals , although clinical and genetic studies suggest that heFH affects \~ 1:200-250 individuals . Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1). Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH disease.

Eligibility Criteria:
Inclusion Criteria:

* both genders
* \>18 years, \<80 years
* door to door enrolment
* eligible to sign informed consent

Exclusion Criteria:

* \<18 years, \>80 years
* deny to sign informed consent
Variable-length Cognitive Processing Therapy for Combat-Related PTSD

The primary goal of this study is to improve the overall efficacy of cognitive processing therapy-cognitive-only version (CPT-C) in a sample of 130 active-duty service members through a variable length treatment.

The primary goal of this study is to improve the overall efficacy of cognitive processing therapy-cognitive-only version (CPT-C) in a sample of 130 active-duty service members through a variable length treatment. The study seeks to determine if some service members would benefit from a longer or shorter dose of treatment (4-24 sessions), and to identify which individuals are likely to require more, less, or the standard number of treatment sessions to reach good end-state functioning. Predictors of length of therapy and treatment outcome will be examined. Specifically, we will evaluate factors related to internalizing/externalizing traits, cognitive flexibility, inability to inhibit dysfunctional cognitions, and readiness to change as they are related to the number of treatment sessions required to treat patients to the point of good end-state functioning. Additional outcomes including alcohol use, psychosocial functioning, physical health, and sleep also will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Adult male and female combat veterans who deployed in support of combat operations following 9/11
* Diagnosis of PTSD determined by a Clinician-Administered Posttraumatic Stress Scale (CAPS-5)
* Speak and read English

Exclusion Criteria:

* Current suicide or homicide risk meriting crisis intervention.
* Active psychosis.
* Moderate to severe brain damage (as determined by the inability to comprehend the baseline screening questionnaires).
* Local availability of fewer than 5 months
* Late-phase Med Board status, awaiting percentages
* Undergoing a chapter
Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions

Compare the rate and extent of absorption of two oral formulations of Ibuprofen 800 mg Tablets, administered as a single, one-tablet dose in fasted subjects.


Eligibility Criteria:
Inclusion Criteria:

* healthy men or women, 18 years of age or older
* body mass index between 19 and 30
* willing to participate and sign a copy of the informed consent form

Exclusion Criteria:

* history of allergy or hypersensitivity to ibuprofen
* recent history of drug or alcohol addiction or abuse
* pregnant or lactating women
* use of tobacco products within 3 months prior to study dosing
* evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
* receipt of any drugs as part of a research study within 30 days prior to study dosing
Single-Session Intervention Targeting Emotional Awareness, Clarity, and Acceptance to Reduce Depression/Anxiety

Two-arm, parallel group randomized clinical trial conducted via Mturk comparing a single-session web-based intervention called Visitor Mindset versus a control intervention (nature videos with relaxing music) for adults with depression and/or anxiety symptoms

Procedures include completing: (1) pre-intervention assessments; (2) one of two single-session web-based intervention (approximately 30 to 45 minutes each); (3) post-intervention assessments, including survey questions following a negative affect induction (brief film clip); and (4) a 2-week follow-up assessment.

Eligibility Criteria:
Inclusion Criteria:

* Adults 18 years and older
* English-speaking
* At least mild anxiety and/or depression symptoms, as indicated by a score of 3 or greater on the 4-item Patient Health Questionnaire (PHQ-4)

Exclusion Criteria:

* fail to meet above-listed inclusion criteria
* exit the study prior to condition randomization
* obvious lack of English fluency in open response questions
* responding with random text in open response questions
* respond with either copy/pasted responses from text earlier in the intervention to any of free response questions
* participants with a completion time less than 180 seconds for the baseline survey assessment (taking about 1.5 seconds per question) OR who fail all three attention check questions in the baseline survey, indicating very careless, random, inattentive and/or hasty responding
Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)

Continuous right ventricular (RV) pacing demonstrates harm in patients with normal left ventricular (LV) function as well as in patients with cardiomyopathy and clinical heart failure. However, little is known about RV pacing in patients with advanced heart failure treated with an implantable left ventricular assist device (LVAD). The univentricular support provided by contemporary continuous flow LVAD's has improved outcomes for many advanced heart failure patients, yet the incidence of RV failure in the early post-operative period following implantation is associated with significantly reduced survival and increased length of stay. Acute LVAD unloading of the left ventricle has adverse effects on RV shape and size that contribute to post-operative RV failure. By promoting RV synchrony, RV overdrive pacing may counteract these adverse mechanical alterations, improving RV systolic function and ultimately LVAD function.

The investigators will recruit all patients referred for an implantable, continuous flow LVAD at Duke University Medical Center who have an existing implantable dual-chamber cardioverter-defibrillator. Patients will be prospectively randomized into two cohorts to compare continuous right ventricular pacing vs. native ventricular conduction at equivalent heart rates. Multiple clinical outcomes will be examined over a two week period post-operatively including invasive hemodynamics, vasoactive medication use, end-organ function, RV function by Echocardiography as well as patient symptoms and functional status.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old, both men and women
* Existing implantable cardioverter-defibrillator (ICD)
* Referred for implantation of a continuous flow LVAD

Exclusion Criteria:

* Permanent left ventricular epicardial defibrillator in place
* Congenital heart disease with single ventricle physiology
* Right ventricular assist device (RVAD) in place
* Existing pacing indication